Neuroinflammation is identified as a central driver of brain atrophy and cognitive decline in Alzheimer’s disease (AD). The present study evaluated the effects of the mesenchymal stem cell therapy laromestrocel (also referred to as Lomecel‑B in study documents) on brain inflammation, brain volume loss, and clinical outcomes in subjects with mild AD.
The report describes outcomes in 49 subjects with mild AD treated within a randomized clinical framework; placebo subjects numbered nine (N=9). Two active dosing regimens are presented: 25 million cells × 4 monthly doses (25Mx4; groups with N reported around 11) and 100 million cells × 4 monthly doses (100Mx4; groups with N reported around 10). Outcomes were assessed through imaging measures of neuroinflammation and brain volume, clinical scales including cognitive testing, and blood biomarker analyses. The primary interval reported is up to 39 weeks following initiation of dosing.
The study reports statistically significant reductions in progressive neuroinflammation in several brain regions implicated in AD when active treatment was compared with placebo at week 39. The most robust effects were observed in typical AD target regions:
Left hippocampus: significant reduction in neuroinflammation for both the 25Mx4 group (p<0.001; N=11) and the 100Mx4 group (p<0.001; N=10) compared with placebo.
Left temporal cortex: significant reduction for the 25Mx4 group (p=0.007; N=11) compared with placebo.
Left parietal cortex: a significant reduction reported for the 25Mx4 group at week 26 (p=0.042; N=10) compared with placebo.
Medulla: significant reductions reported for both 25Mx4 and 100Mx4 groups (p=0.007; N=11 and N=10 respectively) vs placebo.
These regional changes are presented as evidence of an anti‑neuroinflammatory effect localized to core AD regions.
Reductions in imaging measures of neuroinflammation correlated with reduced brain tissue loss and better clinical outcomes. Specifically, decreased neuroinflammation correlated with reduced hippocampal atrophy (correlation coefficient R = -0.326; p=0.040; N=40). Imaging–clinical correlations also favored cognitive function: hippocampal neuroinflammation measures correlated with the Montreal Cognitive Assessment (MoCA) score (hippocampus × MoCA: R = -0.401; p=0.011; N=40). These reported associations link the anti‑inflammatory imaging findings to both structural preservation and measurable cognitive benefit over the study period.
Treated subjects showed changes in plasma biomarkers consistent with reduced synaptic loss and peripheral immune engagement. Plasma neurogranin—a biomarker associated with synaptic injury—was reduced in the 25Mx4 group (p=0.023; N=11), which the authors interpret as consistent with decreased synaptic degeneration. The blood biomarker profile is reported to support a convergent multimodal mechanism of action in which peripheral immune modulation accompanies central anti‑neuroinflammatory effects.
Ethical oversight for the CLEAR MIND study was provided by the Western‑Copernicus Group Institutional Review Board (WCG IRB), with approval dated 24 November 2021 for protocol v2.0 and associated documents. The trial is registered as Clinical Trial NCT05233774. The authors declare competing interests: Dr. Joshua M. Hare reports patents and equity positions and professional relationships with entities including Longeveron Inc.; other relationships and disclosures are detailed in the source document. The report states that the minimum dataset (without individual patient data), the trial protocol, and the statistical analysis plan under US FDA IND #16524 may be shared on request under a data use agreement for IRB‑approved research.
The authors conclude that laromestrocel produces long‑lasting anti‑neuroinflammatory effects in subjects with mild AD, with the strongest imaging effects in left hippocampus, left temporal cortex, left parietal cortex (at week 26 for one comparison), and medulla. These anti‑inflammatory changes correlated with less hippocampal atrophy and with improvements in cognitive measures such as the MoCA. Plasma biomarker changes, including reduced neurogranin in the 25Mx4 group, are presented as concordant evidence of reduced synaptic injury and a peripheral immune component to the mechanism.
Collectively, the reported data support the interpretation that mesenchymal stem cell therapy with laromestrocel can mitigate brain inflammation and is associated with reduced tissue destruction and improved clinical function over the follow‑up interval described.
Notes on reporting and data availability: the source provides details on IRB approval, trial registration, and procedures for data access; it also discloses financial and intellectual‑property relationships for some authors. The source does not provide additional methodological detail beyond what is summarized here; requests for the minimum dataset, protocol, and statistical analysis plan can be made to the corresponding authors.